Literature DB >> 7694815

Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer.

P Stieber1, H Bodenmüller, D Banauch, U Hasholzner, A Dessauer, B Ofenloch-Hähnle, D Jaworek, A Fateh-Moghadam.   

Abstract

We developed a new and automated assay for the detection of lung cancer associated cytokeratin 19 fragments in patients' sera/plasma. This new tumour marker assay CYFRA 21-1 was evaluated in technical and clinical studies using the multibatch analysers ES 300 and ES 600 from Boehringer Mannheim GmbH. The analytical performance was shown to be excellent. The clinical data from 2,037 patients demonstrate that for non-small-cell lung carcinoma CYFRA 21-1 has a higher diagnostic sensitivity compared to the established markers. Mainly for squamous cell carcinoma CYFRA 21-1 was superior (60%) to CEA (18%) or SCC (31%).

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7694815     DOI： 10.1016/0009-9120(93)90129-t

Source DB:  PubMed          Journal:  Clin Biochem        ISSN： 0009-9120            Impact factor:   3.281


  9 in total

1.  Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.

Authors:  Minkyu Jung; Se Hyun Kim; Young Joo Lee; Soojung Hong; Young Ae Kang; Se Kyu Kim; Joon Chang; Sun Young Rha; Joo Hang Kim; Dae Joon Kim; Byoung Chul Cho
Journal:  Exp Ther Med       Date:  2011-05-12       Impact factor: 2.447

2.  Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Li Huang; Wei Chen; Peiwen Liang; Wenjie Hu; Kunsong Zhang; Shunli Shen; Jiancong Chen; Zhaohui Zhang; Bin Chen; Yuyan Han; Fanyin Meng; Sharon DeMorrow; Xiaoyu Yin; Jiaming Lai; Lijian Liang
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

3.  Relationship between pre-treatment serum SCC (squamous cell carcinoma) antigen, Cyfra 21-1 levels, and survival in squamous cell carcinoma of the uterine cervix.

Authors:  Ki-Hong Chang; Hee-Sug Ryu; Suk-Joon Chang; Young-Ji Byun; Jung-Pil Lee
Journal:  Cancer Res Treat       Date:  2005-10-31       Impact factor: 4.679

4.  Molecular analysis of cross-reactive human monoclonal antibody AE6F4 generated by in vitro immunization: Epitope mapping of AE6F4 antibody on 14-3-3 family proteins and cytokeratin 8.

Authors:  A Ichikawa; S Y Shim; Y Katakura; K Teruya; S Hashizume; S Shirahata
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

5.  A multi-analyte serum test for the detection of non-small cell lung cancer.

Authors:  E C Farlow; M S Vercillo; J S Coon; S Basu; A W Kim; L P Faber; W H Warren; P Bonomi; M J Liptay; J A Borgia
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

6.  Clinical significance of serum CYFRA 21-1 in gastric cancer.

Authors:  B Nakata; Y S Chung; Y Kato; M Ogawa; Y Ogawa; A Inui; K Maeda; T Sawada; M Sowa
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

7.  Word Embedding Reveals Cyfra 21-1 as a Biomarker for Chronic Obstructive Pulmonary Disease.

Authors:  Jeongwon Heo; Da Hye Moon; Yoonki Hong; So Hyeon Bak; Jeeyoung Kim; Joo Hyun Park; Byoung-Doo Oh; Yu-Seop Kim; Woo Jin Kim
Journal:  J Korean Med Sci       Date:  2021-09-06       Impact factor: 2.153

8.  Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.

Authors:  Minkyu Jung; Se Hyun Kim; Soojung Hong; Young Ae Kang; Se Kyu Kim; Joon Chang; Sun Young Rha; Joo Hang Kim; Dae Joon Kim; Byoung Chul Cho
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

9.  Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.

Authors:  B Nakata; T Takashima; Y Ogawa; T Ishikawa; K Hirakawa
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.